{"id":32941,"date":"2017-11-28T12:22:39","date_gmt":"2017-11-28T12:22:39","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=32941"},"modified":"2017-11-29T09:13:02","modified_gmt":"2017-11-29T09:13:02","slug":"dolutegravir-use-in-pregnancy-results-from-small-belgian-cohort","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/32941","title":{"rendered":"Dolutegravir use in pregnancy: results from small Belgian cohort"},"content":{"rendered":"<p><strong>Polly Clayden, HIV i-Base<\/strong><\/p>\n<p><strong><img loading=\"lazy\" decoding=\"async\" class=\"alignright size-medium wp-image-32839\" src=\"https:\/\/i-base.info\/htb\/wp-content\/uploads\/2017\/10\/EACS-logo-300x195.png\" alt=\"\" width=\"300\" height=\"195\" srcset=\"https:\/\/i-base.info\/htb\/wp-content\/uploads\/2017\/10\/EACS-logo-300x195.png 300w, https:\/\/i-base.info\/htb\/wp-content\/uploads\/2017\/10\/EACS-logo.png 745w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/>There were no vertical transmissions, obstetrical complications or birth defects among 11 dolutegravir (DTG)-exposed pregnancies at a Brussels-based centre between November 2015 and June 2017.<\/strong><\/p>\n<p>Preliminary data from a prospective observational study of pregnant women and their children exposed to DTG at H\u00f4pital Erasme were presented at EACS 2017.<\/p>\n<p>The women were a median of 33 years old and were all ART-experienced before pregnancy. Eight women were receiving a DTG-containing regimen at conception and already virologically suppressed. The remaining three started a DTG-containing regimen during pregnancy (14, 16 and 26 weeks gestation).<\/p>\n<p>Of 11 women, two experienced blips during pregnancy at nine and 32 weeks gestation: 66 and 1743 copies\/mL respectively. All women had viral loads &lt;40 copies\/mL at delivery.<\/p>\n<p>There was one twin pregnancy and no obstetrical or peri-partum complications.<\/p>\n<p>All infants received four weeks AZT prophylaxis and remained HIV negative at 0, 1, 2 and 3 months (PCR DNA and RNA testing). Long term follow up of the infants is ongoing.<\/p>\n<p>Reference:<\/p>\n<p>Henrard S et al. Clinical outcome of 11 pregnancies with a dolutegravir containing regimen. 16th European AIDS Conference. 25-27 October 2017, Milan. Poster abstract PE9\/66.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Polly Clayden, HIV i-Base There were no vertical transmissions, obstetrical complications or birth defects among 11 dolutegravir (DTG)-exposed pregnancies at a Brussels-based centre between November 2015 and June 2017. Preliminary data from a prospective observational study of pregnant women and &hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,35],"tags":[246],"class_list":["post-32941","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-pmtct-and-maternal-health","tag-eacs-16-milan-2017"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/32941","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=32941"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/32941\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=32941"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=32941"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=32941"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}